The “Prostate Cancer Vaccines Industry Forecast” looks at past sales and reviews total world Prostate Cancer Vaccines sales in 2022, providing a comprehensive analysis by region and market sector of projected Prostate Cancer Vaccines sales for 2023 through 2029. With Prostate Cancer Vaccines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Prostate Cancer Vaccines industry.
This Insight Report provides a comprehensive analysis of the global Prostate Cancer Vaccines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Prostate Cancer Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Prostate Cancer Vaccines market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Prostate Cancer Vaccines and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Prostate Cancer Vaccines.
The global Prostate Cancer Vaccines market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Prostate Cancer Vaccines is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Prostate Cancer Vaccines is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Prostate Cancer Vaccines is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Prostate Cancer Vaccines players cover Dendreon Corporation, Bavarian Nordic, Advantagene, OncBioMune Pharmaceuticals, Advaxis immunotherapies, SOTIO, Cleveland BioLabs Inc., Curevac AG and Mediolanum Farmaceutici, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Prostate Cancer Vaccines market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Tablet
Injection
Segmentation by application
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Dendreon Corporation
Bavarian Nordic
Advantagene
OncBioMune Pharmaceuticals
Advaxis immunotherapies
SOTIO
Cleveland BioLabs Inc.
Curevac AG
Mediolanum Farmaceutici
Pfizer Inc.
Vaccitech
Sensei Biotherapeutics
Medigene AG
Ultimovacs
Oncovir Inc.
UbiVac
Momotaro-Gene Inc.
Vaccibody AS
AlphaVax Inc.
Key Questions Addressed in this Report
What is the 10-year outlook for the global Prostate Cancer Vaccines market?
What factors are driving Prostate Cancer Vaccines market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Prostate Cancer Vaccines market opportunities vary by end market size?
How does Prostate Cancer Vaccines break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Prostate Cancer Vaccines Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Prostate Cancer Vaccines by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Prostate Cancer Vaccines by Country/Region, 2018, 2022 & 2029
2.2 Prostate Cancer Vaccines Segment by Type
2.2.1 Tablet
2.2.2 Injection
2.3 Prostate Cancer Vaccines Sales by Type
2.3.1 Global Prostate Cancer Vaccines Sales Market Share by Type (2018-2023)
2.3.2 Global Prostate Cancer Vaccines Revenue and Market Share by Type (2018-2023)
2.3.3 Global Prostate Cancer Vaccines Sale Price by Type (2018-2023)
2.4 Prostate Cancer Vaccines Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Prostate Cancer Vaccines Sales by Application
2.5.1 Global Prostate Cancer Vaccines Sale Market Share by Application (2018-2023)
2.5.2 Global Prostate Cancer Vaccines Revenue and Market Share by Application (2018-2023)
2.5.3 Global Prostate Cancer Vaccines Sale Price by Application (2018-2023)
3 Global Prostate Cancer Vaccines by Company
3.1 Global Prostate Cancer Vaccines Breakdown Data by Company
3.1.1 Global Prostate Cancer Vaccines Annual Sales by Company (2018-2023)
3.1.2 Global Prostate Cancer Vaccines Sales Market Share by Company (2018-2023)
3.2 Global Prostate Cancer Vaccines Annual Revenue by Company (2018-2023)
3.2.1 Global Prostate Cancer Vaccines Revenue by Company (2018-2023)
3.2.2 Global Prostate Cancer Vaccines Revenue Market Share by Company (2018-2023)
3.3 Global Prostate Cancer Vaccines Sale Price by Company
3.4 Key Manufacturers Prostate Cancer Vaccines Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Prostate Cancer Vaccines Product Location Distribution
3.4.2 Players Prostate Cancer Vaccines Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Prostate Cancer Vaccines by Geographic Region
4.1 World Historic Prostate Cancer Vaccines Market Size by Geographic Region (2018-2023)
4.1.1 Global Prostate Cancer Vaccines Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Prostate Cancer Vaccines Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Prostate Cancer Vaccines Market Size by Country/Region (2018-2023)
4.2.1 Global Prostate Cancer Vaccines Annual Sales by Country/Region (2018-2023)
4.2.2 Global Prostate Cancer Vaccines Annual Revenue by Country/Region (2018-2023)
4.3 Americas Prostate Cancer Vaccines Sales Growth
4.4 APAC Prostate Cancer Vaccines Sales Growth
4.5 Europe Prostate Cancer Vaccines Sales Growth
4.6 Middle East & Africa Prostate Cancer Vaccines Sales Growth
5 Americas
5.1 Americas Prostate Cancer Vaccines Sales by Country
5.1.1 Americas Prostate Cancer Vaccines Sales by Country (2018-2023)
5.1.2 Americas Prostate Cancer Vaccines Revenue by Country (2018-2023)
5.2 Americas Prostate Cancer Vaccines Sales by Type
5.3 Americas Prostate Cancer Vaccines Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Prostate Cancer Vaccines Sales by Region
6.1.1 APAC Prostate Cancer Vaccines Sales by Region (2018-2023)
6.1.2 APAC Prostate Cancer Vaccines Revenue by Region (2018-2023)
6.2 APAC Prostate Cancer Vaccines Sales by Type
6.3 APAC Prostate Cancer Vaccines Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Prostate Cancer Vaccines by Country
7.1.1 Europe Prostate Cancer Vaccines Sales by Country (2018-2023)
7.1.2 Europe Prostate Cancer Vaccines Revenue by Country (2018-2023)
7.2 Europe Prostate Cancer Vaccines Sales by Type
7.3 Europe Prostate Cancer Vaccines Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Prostate Cancer Vaccines by Country
8.1.1 Middle East & Africa Prostate Cancer Vaccines Sales by Country (2018-2023)
8.1.2 Middle East & Africa Prostate Cancer Vaccines Revenue by Country (2018-2023)
8.2 Middle East & Africa Prostate Cancer Vaccines Sales by Type
8.3 Middle East & Africa Prostate Cancer Vaccines Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Prostate Cancer Vaccines
10.3 Manufacturing Process Analysis of Prostate Cancer Vaccines
10.4 Industry Chain Structure of Prostate Cancer Vaccines
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Prostate Cancer Vaccines Distributors
11.3 Prostate Cancer Vaccines Customer
12 World Forecast Review for Prostate Cancer Vaccines by Geographic Region
12.1 Global Prostate Cancer Vaccines Market Size Forecast by Region
12.1.1 Global Prostate Cancer Vaccines Forecast by Region (2024-2029)
12.1.2 Global Prostate Cancer Vaccines Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Prostate Cancer Vaccines Forecast by Type
12.7 Global Prostate Cancer Vaccines Forecast by Application
13 Key Players Analysis
13.1 Dendreon Corporation
13.1.1 Dendreon Corporation Company Information
13.1.2 Dendreon Corporation Prostate Cancer Vaccines Product Portfolios and Specifications
13.1.3 Dendreon Corporation Prostate Cancer Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Dendreon Corporation Main Business Overview
13.1.5 Dendreon Corporation Latest Developments
13.2 Bavarian Nordic
13.2.1 Bavarian Nordic Company Information
13.2.2 Bavarian Nordic Prostate Cancer Vaccines Product Portfolios and Specifications
13.2.3 Bavarian Nordic Prostate Cancer Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Bavarian Nordic Main Business Overview
13.2.5 Bavarian Nordic Latest Developments
13.3 Advantagene
13.3.1 Advantagene Company Information
13.3.2 Advantagene Prostate Cancer Vaccines Product Portfolios and Specifications
13.3.3 Advantagene Prostate Cancer Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Advantagene Main Business Overview
13.3.5 Advantagene Latest Developments
13.4 OncBioMune Pharmaceuticals
13.4.1 OncBioMune Pharmaceuticals Company Information
13.4.2 OncBioMune Pharmaceuticals Prostate Cancer Vaccines Product Portfolios and Specifications
13.4.3 OncBioMune Pharmaceuticals Prostate Cancer Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 OncBioMune Pharmaceuticals Main Business Overview
13.4.5 OncBioMune Pharmaceuticals Latest Developments
13.5 Advaxis immunotherapies
13.5.1 Advaxis immunotherapies Company Information
13.5.2 Advaxis immunotherapies Prostate Cancer Vaccines Product Portfolios and Specifications
13.5.3 Advaxis immunotherapies Prostate Cancer Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Advaxis immunotherapies Main Business Overview
13.5.5 Advaxis immunotherapies Latest Developments
13.6 SOTIO
13.6.1 SOTIO Company Information
13.6.2 SOTIO Prostate Cancer Vaccines Product Portfolios and Specifications
13.6.3 SOTIO Prostate Cancer Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 SOTIO Main Business Overview
13.6.5 SOTIO Latest Developments
13.7 Cleveland BioLabs Inc.
13.7.1 Cleveland BioLabs Inc. Company Information
13.7.2 Cleveland BioLabs Inc. Prostate Cancer Vaccines Product Portfolios and Specifications
13.7.3 Cleveland BioLabs Inc. Prostate Cancer Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Cleveland BioLabs Inc. Main Business Overview
13.7.5 Cleveland BioLabs Inc. Latest Developments
13.8 Curevac AG
13.8.1 Curevac AG Company Information
13.8.2 Curevac AG Prostate Cancer Vaccines Product Portfolios and Specifications
13.8.3 Curevac AG Prostate Cancer Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Curevac AG Main Business Overview
13.8.5 Curevac AG Latest Developments
13.9 Mediolanum Farmaceutici
13.9.1 Mediolanum Farmaceutici Company Information
13.9.2 Mediolanum Farmaceutici Prostate Cancer Vaccines Product Portfolios and Specifications
13.9.3 Mediolanum Farmaceutici Prostate Cancer Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Mediolanum Farmaceutici Main Business Overview
13.9.5 Mediolanum Farmaceutici Latest Developments
13.10 Pfizer Inc.
13.10.1 Pfizer Inc. Company Information
13.10.2 Pfizer Inc. Prostate Cancer Vaccines Product Portfolios and Specifications
13.10.3 Pfizer Inc. Prostate Cancer Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Pfizer Inc. Main Business Overview
13.10.5 Pfizer Inc. Latest Developments
13.11 Vaccitech
13.11.1 Vaccitech Company Information
13.11.2 Vaccitech Prostate Cancer Vaccines Product Portfolios and Specifications
13.11.3 Vaccitech Prostate Cancer Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Vaccitech Main Business Overview
13.11.5 Vaccitech Latest Developments
13.12 Sensei Biotherapeutics
13.12.1 Sensei Biotherapeutics Company Information
13.12.2 Sensei Biotherapeutics Prostate Cancer Vaccines Product Portfolios and Specifications
13.12.3 Sensei Biotherapeutics Prostate Cancer Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Sensei Biotherapeutics Main Business Overview
13.12.5 Sensei Biotherapeutics Latest Developments
13.13 Medigene AG
13.13.1 Medigene AG Company Information
13.13.2 Medigene AG Prostate Cancer Vaccines Product Portfolios and Specifications
13.13.3 Medigene AG Prostate Cancer Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Medigene AG Main Business Overview
13.13.5 Medigene AG Latest Developments
13.14 Ultimovacs
13.14.1 Ultimovacs Company Information
13.14.2 Ultimovacs Prostate Cancer Vaccines Product Portfolios and Specifications
13.14.3 Ultimovacs Prostate Cancer Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Ultimovacs Main Business Overview
13.14.5 Ultimovacs Latest Developments
13.15 Oncovir Inc.
13.15.1 Oncovir Inc. Company Information
13.15.2 Oncovir Inc. Prostate Cancer Vaccines Product Portfolios and Specifications
13.15.3 Oncovir Inc. Prostate Cancer Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Oncovir Inc. Main Business Overview
13.15.5 Oncovir Inc. Latest Developments
13.16 UbiVac
13.16.1 UbiVac Company Information
13.16.2 UbiVac Prostate Cancer Vaccines Product Portfolios and Specifications
13.16.3 UbiVac Prostate Cancer Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 UbiVac Main Business Overview
13.16.5 UbiVac Latest Developments
13.17 Momotaro-Gene Inc.
13.17.1 Momotaro-Gene Inc. Company Information
13.17.2 Momotaro-Gene Inc. Prostate Cancer Vaccines Product Portfolios and Specifications
13.17.3 Momotaro-Gene Inc. Prostate Cancer Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 Momotaro-Gene Inc. Main Business Overview
13.17.5 Momotaro-Gene Inc. Latest Developments
13.18 Vaccibody AS
13.18.1 Vaccibody AS Company Information
13.18.2 Vaccibody AS Prostate Cancer Vaccines Product Portfolios and Specifications
13.18.3 Vaccibody AS Prostate Cancer Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.18.4 Vaccibody AS Main Business Overview
13.18.5 Vaccibody AS Latest Developments
13.19 AlphaVax Inc.
13.19.1 AlphaVax Inc. Company Information
13.19.2 AlphaVax Inc. Prostate Cancer Vaccines Product Portfolios and Specifications
13.19.3 AlphaVax Inc. Prostate Cancer Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
13.19.4 AlphaVax Inc. Main Business Overview
13.19.5 AlphaVax Inc. Latest Developments
14 Research Findings and Conclusion
*If Applicable.